Stephen V Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics and Associate Professor at the Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Overview of ROS1 in NSCLC by Dr. Fabrice Barlesi at Rome Lung 2025?
Three approved drugs – crizotinib, entrectinib, most recently, repotrectinib – all very active agents. At progression, lorlatinib may be an option at progression but chemotherapy is active with emerging agents like NVL -510.”
More posts featuring Stephen V Liu on OncoDaily.
